X

HSA Reclassified Drug | Exemptions For Supply of Levocetirizine tablet Without Prescription

Criteria

Eligible Active Ingredient: Levocetirizine tablet. As an oral solid preparation containing not more than 5mg
With Effective From: 1-Jul-2012
Indication Permitted: For the symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria.
Maximum Daily Dose: 5mg
Maximum Supply per Transaction: 10 tablets
Minimum Age of User: 12 years
Patient Information Leaflet from HSA/PSS: Download PIL (Link to HSA website)

Mechanism of Action of Levocetirizine tablet

Levocetirizine, the active enantiomer of cetirizine, is an anti-histamine; its principal effects are mediated via selective inhibition of H1 receptors. The antihistaminic activity of levocetirizine has been documented in a variety of animal and human models. In vitro binding studies revealed that levocetirizine has an affinity for the human H1-receptor 2-fold higher than that of cetirizine (Ki = 3 nmol/L vs. 6 nmol/L, respectively). This increased affinity has unknown clinical relevance.

Additional Information of Levocetirizine tablet

Pharmacology Class: Antihistamines For Systemic Use
Therapeutic Class: Antihistamines For Systemic Use
Chemical Class: Piperazine Derivatives
Synonyms: 2-(2-{4-[(R)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid

Show All HSA-registered therapeutic products granted exemption to supply without prescription

References

  1. Health Science Authority of Singapore – Reclassified POM
  2. Drugbank

HSA-Registered Products Containing Levocetirizine tablet As an oral solid preparation containing not more than 5mg

wpDataTable with provided ID not found!

This list is not exhaustive. HSA collaborates with Pharmaceurical Society of Singapore (PSS) to review the appropriate use of therapeutic products in the community from time to time. Hence, HSA may enable the supply of a Prescription Only Medicine (POM) by pharmacists without a prescription, upon review that the product can be used in a safe and effective manner under the supervision of a pharmacist. This can be effected through legislative mechanisms in the absence of an application made by the product registrant to reclassify the therapeutic product, subject to to conditions including indication, strength, maximum daily dose, maximum supply quantity, and age restriction.

Pharmfair.com uses cookies to improve your browsing experience. We'll assume you're ok with this, but you can opt-out if you wish. Peace!